Literature DB >> 2927582

Perinatal treatment with glucocorticoids and the risk of maldevelopment of the brain.

O Benesová1, A Pavlík.   

Abstract

Drugs administered during the perinatal period reach the developing organism at the vulnerable stage of intensive brain histogenesis and cytodifferentiation. They may interfere with the programme of developmental processes in the brain and lead to disturbances at the cellular/subcellular level and to biochemical alterations. These abnormalities form the basis for the functional pathology which becomes apparent gradually during maturation or even in adulthood as neuropsycho-behavioural deviations. A model experimental study in rats was carried out with synthetic glucocorticoids, which are widely used in obstetrics and neonatology for the prevention and treatment of neonatal idiopathic respiratory distress syndrome. As the developmental stage of the brain of the human foetus in late pregnancy closely resembles the ontogenetic phases of the brain of the rat in the early postnatal period, the neonate rat was taken as a model. The administration of dexamethasone to 7-day-old rats resulted in significant depletion of glucocorticoid receptors from the cytosol of the brain in a dose-dependent manner, beginning with the dose of 0.04 mg/kg (s.c.), i.e. a dose one order lower than the clinical dose used in obstetrics (0.4-0.5 mg/kg). Long-term follow-up of a single neonatal injection of dexamethasone (0.2 or 1 mg/kg s.c. on postnatal day 7) revealed an acceleration of some developmental landmarks in the preweaning period (incisor eruption, eye opening, motor skill) on the one hand, but a retardation of body growth and vaginal opening on the other hand. Adult animals exhibited a deficit in motor co-ordination, behavioural deviations (hyperactivity with stereotypy, decreased adaptability, increased emotional reactivity) and disturbances in reproduction in both males and females.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2927582     DOI: 10.1016/0028-3908(89)90073-7

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  18 in total

Review 1.  Postnatal steroid treatment and brain development.

Authors:  O Baud
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-03       Impact factor: 5.747

2.  Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants.

Authors:  Ann R Stark; Waldemar A Carlo; Betty R Vohr; Lu Ann Papile; Shampa Saha; Charles R Bauer; William Oh; Seetha Shankaran; Jon E Tyson; Linda L Wright; W Kenneth Poole; Abhik Das; Barbara J Stoll; Avroy A Fanaroff; Sheldon B Korones; Richard A Ehrenkranz; David K Stevenson; Myriam Peralta-Carcelen; Deanne E Wilson-Costello; Henrietta S Bada; Roy J Heyne; Yvette R Johnson; Kimberly Gronsman Lee; Jean J Steichen
Journal:  J Pediatr       Date:  2013-08-27       Impact factor: 4.406

3.  Can Placental Corticotropin-Releasing Hormone Inform Timing of Antenatal Corticosteroid Administration?

Authors:  Danielle A Swales; Leah A Grande; Deborah A Wing; Michelle Edelmann; Laura M Glynn; Curt Sandman; Roger Smith; Maria Bowman; Elysia Poggi Davis
Journal:  J Clin Endocrinol Metab       Date:  2019-02-01       Impact factor: 5.958

4.  Regulation of corticoid and serotonin receptor brain system following early life exposure of glucocorticoids: long term implications for the neurobiology of mood.

Authors:  Delia M Vázquez; Charles R Neal; Paresh D Patel; Niko Kaciroti; Juan F López
Journal:  Psychoneuroendocrinology       Date:  2011-08-19       Impact factor: 4.905

5.  Glucocorticoid receptor stimulation and the regulation of neonatal cerebellar neural progenitor cell apoptosis.

Authors:  Kevin K Noguchi; Karen Lau; Derek J Smith; Brant S Swiney; Nuri B Farber
Journal:  Neurobiol Dis       Date:  2011-04-20       Impact factor: 5.996

6.  Early postnatal dexamethasone treatment and increased incidence of cerebral palsy.

Authors:  E S Shinwell; M Karplus; D Reich; Z Weintraub; S Blazer; D Bader; S Yurman; T Dolfin; A Kogan; S Dollberg; E Arbel; M Goldberg; I Gur; N Naor; L Sirota; S Mogilner; A Zaritsky; M Barak; E Gottfried
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-11       Impact factor: 5.747

7.  A psychoneuroimmunologic examination of cumulative perinatal steroid exposures and preterm infant behavioral follow-up.

Authors:  Isabell B Purdy; Lynne Smith; Dorothy Wiley; Lina Badr
Journal:  Biol Res Nurs       Date:  2011-09-07       Impact factor: 2.522

8.  A survey of the administration of drugs to young infants. The Alspac Survey Team. Avon Longitudinal Study of Pregnancy and Childhood.

Authors:  N Hawkins; J Golding
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

9.  Cumulative perinatal steroids: child development of preterm infants.

Authors:  Isabell B Purdy; Dorothy J Wiley; Lynne M Smith; Carollee Howes; Anna Gawlinski; Wendy Robbins; Lina K Badr
Journal:  J Pediatr Nurs       Date:  2008-06       Impact factor: 2.145

10.  Acute neonatal glucocorticoid exposure produces selective and rapid cerebellar neural progenitor cell apoptotic death.

Authors:  K K Noguchi; K C Walls; D F Wozniak; J W Olney; K A Roth; N B Farber
Journal:  Cell Death Differ       Date:  2008-07-04       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.